| Cat.No. | Name | Information |
|---|---|---|
| M2206 | TH-302 (Evofosfamide) | TH-302 is a highly potent and selective hypoxia-activated procompound targeting hypoxic regions of solid tumors with IC50 of 19 nM. |
| M6098 | Baicalein | Baicalein is a CYP2C9 and prolyl endopeptidase inhibitor, IC50 value of 3.12 mM. |
| M9325 | EGTA | EGTA is a specific calcium chelator with a Kd of 60.5 nM at physiological pH (7.4) and a high specificity for Ca2+ than for Mg2+.EGTA significantly inhibits the substrate adhesion capacity of inflammatory macrophages. |
| M9330 | Brij-35 | Brij-35 (Polidocanol) is a high HLB, ethoxylated, nonionic ether of lauryl alcohol with broad pH stability. |
| M6154 | 2-PMPA tetrasodium | 2-PMPA (PMPA tetrasodium salt) is a potent and selective inhibitor of glutamate carboxypeptidase II (GCPII) with an IC50 of 300 pM. |
| M2250 | Pamidronate disodium | Pamidronate disodium is a nitrogen containing bisphosphonate, used to the research of preventing osteoporosis. |
| M9916 | DPPH | DPPH (2,2-Diphenyl-1-picrylhydrazyl) is a stable free radical that measures the free radical scavenging activity of antioxidants. |
| M9194 | Insulin (human) | Insulin (human) is a polypeptide hormone that regulates the level of sugar (glucose) in the blood and is produced by beta cells of islets. |
| M3409 | Formestane | Formestane is a second generation selective aromatase inhibitor with an IC50 of 80 nM. |
| M9665 | N-(2-amino-2-oxoethyl)acrylamide | N-(2-Amino-2-oxoethyl)acrylamide |
| M24917 | Zampilimab | Zampilimab (UCB-7858) is a monoclonal antibody against transglutaminase 2 (TG2). Zampilimab has potential application in renal transplant, and relevant research is still ongoing. |
| M24901 | Obrindatamab | Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer. |
| M24897 | Epratuzumab | Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases. |
| M24896 | Murlentamab | Murlentamab (3C23K; GM102) is a humanized anti-AMHRII antibody. AMHRII is the anti-Müllerian hormone receptor. Murlentama significantly promotes macrophage-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Murlentama stimulates pro-inflammatory and anti-tumor internal environment, recruits and activates T cells. Murlentama suppresses tumors growth by inducing naïve macrophage orientation and promoting tumor-associated macrophage (TAM) reprogramming. |
| M24887 | Torapsel | Torapsel (42-89-glycoprotein; WAY164339) is a fusion protein with immunoglobiln. Torapsel can be used to research the prevention of ischemia reperfusion injury. |
| M24886 | Tepoditamab | Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab (MCLA-117) kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research. |
| M24884 | Vopratelimab | Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that pecifically binds to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response. |
| M24880 | Morolimumab | Morolimumab is an IgG1 human anti-RHD/CD240D monoclonal antibody. Morolimumab can be used for the research of immune disease. |
| M24877 | Cobolimab | Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC50 value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC). |
| M24874 | Imaprelimab | Imaprelimab (PRX-003) is a humanized IgG1κ anti-melanoma cell adhesion molecule (MCAM) monoclonal antibody. Imaprelimab is an antineoplastic agent. |
| M24866 | Prasinezumab | Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research. |
| M24863 | Bifikafusp alfa | Bifikafusp alfa (L19-IL2) is an immunotherapy fusion protein consisting of human L19 antibodies fused to the human cytokine interleukin 2 (IL2).Bifikafusp alfa is specific to the EDB domain of fibronectin. Bifikafusp alfa has anticancer activity. |
| M24861 | Anetumab | Anetumab (Anti-MSLN Antibody) is an anti-mesothelin (MSLN) antibody. MSLN is a tumor-associated antigen. Anetumab can be used to synthesis Anetumab ravtansine, a MSLN-targeting antibody-drug conjugate (ADC). Anetumab can be used for the research of malignant tumor. |
| M24860 | Minretumomab | Minretumomab (CC-49) is a mouse anti-TAG-72 (tumor-associated glycoprotein 72) monoclonal antibody and a radioimmunoconjugate. Minretumomab can be used for the research of cancer and radioimmunotherapy (RIT). |
| M24859 | Vepalimomab | Vepalimomab (Anti-Human AOC3 Recombinant Antibody) is a monoclonal antibody that blocks vascular adhesion protein 1 (VAP-1). Vepalimomab has anti-inflammatory effects. |
| M24857 | Berlimatoxumab | Berlimatoxumab (ASN-2) is an antibody. Berlimatoxumab can be used for experiment research. |
| M24856 | Atidortoxumab | Atidortoxumab is a human IgG1κ monoclonal antibody that targets Staph aureus alpha toxin. |
| M24854 | Ianalumab | Ianalumab (VAY-736) is a humanized, decarboxylated antibody against BAFF-R. Ianalumab can block the interaction between BAFF and BAFF-R and antagonize the apoptosis protection mediated by BAFF. Ianalumab exerts antibody-dependent cytotoxic (ADCC), depending on effector cell activation mediated by immune receptor tyrosine activation motif (ITAM). |
| M24844 | Omburtamab | Omburtamab is an anti-CD276 (also known as B7-H3) monoclonal antibody, CD276 is a B7/CD28 immunoglobulin superfamily member expressed among solid human tumours. Omburtamab can bind tumor tissues and be used in various cancers research. |
| M24838 | Loncastuximab | Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab shows antitumor activity and has potential application in non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
